Condition
    Effectiveness 3/5

    Vitamin B3 for High Cholesterol (Dyslipidemia)

    Niacin produces the best lipid-panel improvement of any single agent, yet two large randomized outcome trials found it did not prevent cardiovascular events when added to statin therapy — and caused harm.

    Overview

    Niacin produces the best lipid-panel improvement of any single agent, yet two large randomized outcome trials found it did not prevent cardiovascular events when added to statin therapy — and caused harm.

    Verdict

    Mixed evidence

    If your goal is better lipid numbers, niacin works. If your goal is fewer heart attacks on top of a statin, it has been tested twice and failed.

    How It Works

    Nicotinic acid inhibits hepatic DGAT-2 and adipocyte lipolysis, cutting VLDL secretion and slowing HDL catabolism.

    Dosing & Protocol

    Typical dose

    Recommended dose
    1-3 g/day nicotinic acid, medically supervised only
    Expected timeframe
    4-8 weeks for lipid change; cardiovascular benefit not demonstrated

    Protocol

    form
    Prescription extended-release nicotinic acid. Immediate-release niacin causes severe flushing; sustained-release forms carry the highest hepatotoxicity risk; and no-flush inositol hexanicotinate does not lower lipids at all
    duration
    Only with a clinician - lipids and liver function rechecked at each step
    co factor
    Take at bedtime with a low-fat snack, and take aspirin 325 mg 30 minutes beforehand to blunt flushing; avoid alcohol and hot drinks around the dose. Evidence is mixed and this distinction matters: niacin genuinely raises HDL by 15-35% and lowers triglycerides and LDL, but the AIM-HIGH and HPS2-THRIVE outcome trials found no reduction in cardiovascular events when added to a statin, and HPS2-THRIVE showed increased serious adverse events including diabetes, infection and bleeding.
    titration
    Increase by 500 mg every four weeks toward 1500-2000 mg/day, with liver enzymes, glucose and uric acid monitored
    starting dose
    Prescription extended-release niacin, started at 500 mg at bedtime under medical supervision only

    Evidence

    What the studies say

    Nicotinic acid at gram doses lowers LDL 15-20%, triglycerides 20-50%, raises HDL 15-35% and reduces lipoprotein(a) — effects no other single agent matches. AIM-HIGH randomized 3,414 patients with established cardiovascular disease and well-controlled LDL to extended-release niacin or placebo on top of simvastatin, and was stopped early for futility: HDL rose and triglycerides fell, but events did not decrease. HPS2-THRIVE randomized 25,673 patients to extended-release niacin plus laropiprant and found no reduction in major vascular events plus significant excesses of diabetes onset, diabetic complications, infection, bleeding and gastrointestinal events. The older Coronary Drug Project did show benefit, but predated statins entirely. The honest reading is that niacin corrects surrogate markers without correcting risk in statin-treated patients. Legitimate remaining roles are pellagra and severe hypertriglyceridemia where pancreatitis risk dominates.

    Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy (AIM-HIGH)

    Score: 9/10
    2011
    rct
    n=3414

    AIM-HIGH Investigators, Boden WE, Probstfield JL +2 more

    Niacin raised HDL cholesterol and lowered triglycerides but produced no reduction in cardiovascular events.

    View source

    Safety considerations with niacin therapy

    Score: 5/10
    2007
    systematic_review

    Guyton JR, Bays HE

    Flushing affects most users of immediate-release niacin and glucose elevation is common in insulin-resistant patients.

    View source

    Safety

    Caveats

    This is a drug dose, not a vitamin dose, and it needs medical supervision. Safety ceiling: the tolerable upper intake level for supplemental niacin is 35 mg/day; lipid doses of 1500-2000 mg/day are 40-60 times that and cause hepatotoxicity (worst with over-the-counter sustained-release forms), raised blood glucose and new-onset diabetes, raised uric acid and gout flares, and increased bleeding and infection risk. Flushing, itching and headache are near-universal at first. Contraindicated in active liver disease, active peptic ulcer and arterial bleeding, and not recommended in pregnancy at lipid-lowering doses. Statins have the outcome evidence niacin lacks - do not self-treat high cholesterol with over-the-counter niacin.

    Less likely to help if

    People already on a statin, in whom adding niacin gave no event reduction and added harm.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.